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Hyperlipidemia represents a determinant in the devel-
opment of atherosclerosis and an important risk factor
for cardiovascular disease. There is a curvilinear relation-
ship between total serum cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), and deaths from coronary
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Hyperlipidemia can be effectively treated either with niacin or HMG-CoA reductase inhibitor (statin), or a
combination of both. Few reports showed the effects of the combination regimen with niacin and statin on
hemostatic functions. We conducted a single-center, double-blind, double-dummy, randomized, two-arm
study to assess the effects of the niacin extended-release/lovastatin therapy in a fixed-dose formulation and
of simvastatin on lipid lowering and two fibrinolytic parameters, fibrinogen and d-dimer. All patients were
enrolled according to NCEP-ATP III guidelines and underwent a placebo run-in period of 4 weeks before
being randomized to either niacin extended-release/lovastatin tablets (500/20 mg) once daily (n = 36) or
simvastatin capsule (20 mg) once daily (n = 34). After 16 weeks of treatment, both groups of patients showed
significantly reduced low-density lipoprotein cholesterol and total cholesterol (LDL-C, p < 0.001 and < 0.001,
respectively, p = 0.159 between the groups; TC, p < 0.001 and < 0.001, respectively, p = 0.018 between the
groups). Both drugs were well tolerated. Only in the group treated with niacin extended-release/lovastatin
was fibrinogen concentration significantly reduced after treatment (2.48 ± 0.65 to 1.99 ± 0.62 g/L, p = 0.008).
No difference was found with d-dimer in either group. This study shows that both niacin extended-release/
lovastatin and simvastatin are effective and well-tolerated lipid-lowering drugs in Taiwanese patients with
dyslipidemia. A combinational treatment with niacin extended-release/lovastatin may provide additional
benefit in fibrinolysis.
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heart disease (CHD) [1]. Increasing levels of high-density
lipoprotein cholesterol (HDL-C) are associated with a
reduced relative risk of CHD. Therefore, the LDL/HDL
cholesterol ratio is useful in assessing the absolute risk of
CHD.
Many large trials showed that lipid lowering can reduce
CHD morbidity and mortality [2,3]. HMG-CoA reductase
inhibitor (statin) can effectively reduce TC, LDL-C,
triglycerides (TG), and increase HDL-C. Pharmacologic
treatment with statin drugs was shown to greatly improve
cardiovascular morbidity and mortality in primary and
secondary prevention studies [4]. Niacin is recognized as
© 2006 Elsevier. All rights reserved.
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the most potent agent available to increase HDL-C. It also
decreased LDL-C and total mortality in secondary
prevention trials [5].
Numerous studies have demonstrated that disturbances
of coagulation and fibrinolysis contribute to the development
and progression of atherosclerosis. It has been established
that the benefits of statin therapy in cardiovascular disease
can be explained not only by the lipid-lowering potential,
but also by nonlipid-related mechanisms and is known as
statin pleiotropic effects, which are partly achieved by their
fibrinolytic ability [6]. Niacin, when added to statins, can
reduce TG, increase HDL-C, and reduce non-HDL-C to a
greater extent than statin monotherapy [7]. We had pre-
viously reported that statin could modulate fibrinolysis [8].
However, the influence of a combination regimen of statin
and niacin on hemostatic parameters is unclear.
Combined use of niacin with a statin is an attractive
option, since these types of medication have the best records
in clinical trials for reduction in cardiovascular events and
improvement in progression/regression of coronary lesions
[7]. Few studies have investigated the effect of combination
treatment on lipid profile in Orientals. This study
investigates the lipid-lowering efficacy and safety of niacin
extended-release plus lovastatin therapy in a fixed-dose
formulation and simvastatin administered orally once daily
for 16 weeks to dyslipidemia patients in Taiwan. We also
tested the change of the two fibrinolytic parameters—
fibrinogen and d-dimer.
SUBJECTS AND METHODS
This was a single-center, double-blind, double-dummy,
randomized, two-arm study comparing the efficacy and
safety of niacin extended-release/lovastatin tablets (500/
20 mg) and simvastatin capsule (20 mg) for the treatment of
dyslipidemia. Physical examination was performed every 4
weeks during the visit. Blood biochemistry and lipid profile
were measured at the central laboratory in Kaohsiung
Medical University Chung-Ho Memorial Hospital. During
each visit, general open-ended questions were given to
monitor any occurrences of adverse events. The study was
approved by the institutional review committee of
Kaohsiung Medical University Hospital. Each study
participant signed an informed consent form.
The inclusion criteria were: (1) * 20 years of age; (2)
failure to control LDL-C level under the 4-week therapeutic
lifestyle changes (TLC); (3) hyperlipidemia diagnosed
according to National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATP III) guidelines:
CHD and CHD risk equivalents (i.e. 10-year risk > 20%)
with LDL-C * 130 mg/dL, * 2 risk factors and 10-year risk
10–20% with LDL-C * 130 mg/dL, * 2 risk factors and
10-year risk < 10% with LDL-C * 160 mg/dL, ) 1 risk factor
with LDL-C * 190 mg/dL [9]; (4) receiving concomitant
treatment other than lipid-control treatment that was
known to affect lipid level and dose maintained unchanged
throughout the study; (5) male/female subject with
reproductive potential is under appropriate contraception;
(6) compliance and geographic proximity to the study site
allowing adequate follow-up; (7) willing to participate in
the trial and sign a written consent.
Those who met the above criteria were excluded if any
of the following was observed: (1) TG > 500 mg/dL; (2)
breast feeding in female subject; (3) pregnancy or not
exercising appropriate birth control during course of study;
(4) type I diabetes; (5) uncontrolled type II diabetes requiring
insulin treatment; (6) uncontrolled hypertension (systolic
blood pressure > 180 mmHg or diastolic blood pressure >
110 mmHg); (7) uncontrolled hypothyroidism; (8) diagnosis
of acute myocardial infarction within the proceeding 3
months; (9) insufficient renal function (serum creatinine >
2.0 mg/dL); (10) insufficient liver function (aspartate ami-
notransferase, AST/alanine aminotransferase, ALT > 2
times normal); (11) diagnosis of severe peptic ulcer disease;
(12) gout attack and hyperuricemia within 1 month
preceding randomization; (13) not able to stop concomitant
lipid-control treatment during the study; (14) history of
hypersensitivity to product being investigated; and (15)
drug or alcohol abuse.
The whole duration of this trial was 25 weeks (i.e.
5-week wash out, 16-week drug treatment, and 4-week
follow-up period). During the 5-week wash out (placebo
run-in) period, each subject discontinued their lipid-
lowering medicine and engaged TLC. Patients were
randomized to one of the following parallel treatment
groups: niacin extended-release plus lovastatin tablets
(500/20 mg) or simvastatin capsule (20 mg). The initial 4
weeks was a titration period. The dose was adjusted
according to the treatment goal suggested by the NCEP-
ATP III guidelines, i.e. CHD and CHD risk equivalents
(i.e. 10-year risk > 20%) to LDL-C < 100 mg/dL, * 2 risk
factors to LDL-C < 130 mg/dL, ) 1 risk factor to LDL-C
< 160 mg/dL [9]. Patients who did not meet the above
criteria after the 4-week treatment were advanced to the
double strength regimen (niacin extended-release plus
lovastatin tablets 1,000/40 mg or simvastatin capsule
40 mg).
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Laboratory evaluation was done at screening, every
4-week visit after active medication, and the end of study.
Fasting blood samples (8-hour fast) were collected for lipid
profile and biochemistry analysis. Whole blood (10 mL) was
collected in sodium citrate tubes and centrifuged for
fibrinolytic parameters. Plasma was frozen at –80°C until
use. Fibrinolytic parameter analysis was done at the end of
the study. Fibrinogen was measured according to the Clauss
clotting method, and d-dimer concentration was measured by
the immunoturbidmetric method (Diagnostica Stago, France).
The primary endpoint of this study was efficacy of
LDL-C decreasing after 16 weeks with either niacin
extended-release plus lovastatin or simvastatin treatment.
The secondary endpoints were the TC, TG, and HDL-C
changes, safety profile and alteration of fibrinolytic
parameters (fibrinogen and d-dimer).
Statistical analysis
All data were expressed as mean ± standard deviation (SD).
All tests were two-sided. A p < 0.05 was considered
statistically significant. Chi-square test and Wilcoxon’s rank-
sum test were used to compare categorical data and
nonparametric data, respectively. The t test was used to
analyze continuous variables. The primary analysis for
efficacy endpoints was performed based on the intent-to-
treat (ITT) population. For primary and secondary
endpoints, percent changes from baseline were compared
between treatment groups by using ANCOVA with one
fixed factor for treatment group and the responding baseline
value as the covariate. SPSS version 11.0 (SPSS Inc, Chicago,
IL, USA) for Windows was used for statistical analysis.
RESULTS
Baseline data
Overall, 164 subjects were screened for enrollment into this
study. Seventy met the inclusion criteria and were
randomized into the two scheduled treatment groups: 36
subjects in the niacin extended-release plus lovastatin group
vs. 34 subjects in the simvastatin group. During the study,
two subjects did not take any study medicine (1 subject in
niacin extended-release plus lovastatin group; 1 subject in
simvastatin group). Seven subjects had no post-treatment
evaluation (4 subjects in combination group; 3 subjects in
simvastatin group). Finally, the ITT group in this study
included 61 subjects (31 subjects in combination group vs.
30 subjects in simvastatin group). The baseline characteristics
of these 61 participants are given in Table 1. There was no
difference between patients taking niacin extended-release
plus lovastatin and simvastatin regarding sex, age, body
weight, height, systolic/diastolic blood pressure, duration
of hyperlipidemia, and criteria for enrollment.
During the study, 16 subjects withdrew from the study (11
subjects in combination group vs. 5 subjects in simvastatin
group). Fourteen subjects withdrew their consent (10 subjects
in combination group and 4 subjects in simvastatin group)
for nonadverse event-related personal reasons or were lost
to follow-up. One subject from the combination group was
withdrawn from the study because of ineffective test drug
(LDL-C level: 200 mg/day after doubling dose). A subject in the
simvastatin group discontinued treatment due to skin itching.
The study was completed, including 25 subjects from the
combination group and 29 subjects from the simvastatin group.
Table 1. Baseline characteristics*
Lovastatin plus niacin Simvastatin
p
(n = 31) (n = 30)
Sex (male, %) 48 60 0.444
Age (yr) 58.2 ± 9.1 58.5 ± 9.7 0.898
Height (cm) 159.6 ± 7.7 161.9 ± 7.5 0.237
Weight (kg) 64.6 ± 12.9 65.0 ± 10.4 0.881
Systolic BP 134.6 ± 18.7 135.7 ± 13.1 0.739
Diastolic BP 81.7 ± 10.5 83.1 ± 9.0 0.942
Duration of hyperlipidemia (mo) 18 ± 3.0 18.9 ± 2.5 0.919
Enrollment criteria (%)
CHD and CHD risk equivalents 71 63
2+ risk factors and 10-year risk 10–20% 26 33
0.578
2+ risk factors and 10-year risk < 10% 3 0
0–1 risk factor 0 3
*Values are shown as mean ± standard deviation. BP = blood pressure; CHD = coronary heart disease.
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Lipid profile
Both treatments significantly reduced LDL-C and TC
compared with baseline (Table 2). LDL-C decreased in
patients taking niacin extended-release plus lovastatin from
161.4 ± 21.6 to 110.8 ± 25.2 mg/dL (p < 0.001). TC dropped
from 241.8 ± 26.2 to 191.0 ± 32.1 mg/dL (p < 0.001). In the
simvastatin group, LDL-C decreased from 159.9 ± 25.6 to
102.1 ± 26.0 mg/dL (p < 0.001), and TC from 238.8 ± 28.3 to
172.7 ±  28.7 mg/dL (p < 0.001). Treatment with niacin
extended-release plus lovastatin, but not with simvastatin,
significantly increased HDL-C compared with baseline
(45.2 ± 11.7 to 49.2 ± 12.5 mg/dL, p = 0.003 and 42.7 ± 8.6
to 43.7 ±  10.7, p = 0.371, respectively). Treatment with
simvastatin, but not with niacin extended-release plus
lovastatin, significantly reduced TG compared with
baseline (155.7 ± 83.2 to 115.2 ± 52.3 mg/dL, p = 0.017 and
129.9 ± 68.8 to 118.4 ± 47.2, p = 0.672, respectively).
There was no difference in LDL-C and TG change
between the combination treatment and simvastatin
(–30.5 ± 17.7 vs. –36.0 ± 13.7% for LDL-C, p = 0.159 and 3.2
±  42.1 vs. –17.1 ±  36.8% for TG, p = 0.136). There was a
significant difference in TC and HDL change between the
groups (–20.6 ± 13.7 vs. –27.5 ± 9.5% for TC, p = 0.018, and
10.4 ± 18.0 vs. 2.2 ± 13.4%, p = 0.029 for HDL).
Tolerability and safety
The severity of adverse events based on the body systems
was dependent on patients’ description and classified as
mild, moderate, and severe. The adverse events were mostly
mild in severity and are shown in Table 3. No statistically
significant difference was found between the two groups.
No drug-related adverse event was reported in this study.
The study medications in the two treatment groups were
generally well tolerated.
There were no significant changes in the biochemistry
data that include BUN, creatinine, and total bilirubin. AST
and ALT increased in subjects receiving combination
treatment but not in those taking simvastatin (26.26 ± 10.24
to 32.50 ± 13.30 U/L, p = 0.005 and 26.55 ± 11.48 to 33.65 ±
16.05 U/L, p = 0.023, respectively). However, the mean
values of each parameter were within the normal range. No
subject was required to discontinue treatment at the
investigator’s discretion.
Fibrinolytic parameters
Of the 54 patients who completed the trial, five in the
lovastatin plus niacin group and seven in the simvastatin
group had no adequate blood sample for examination of
fibrinolytic parameters. The remaining 42 patients (20 in
niacin extended-release plus lovastatin; 22 in simvastatin
group) received evaluation of fibrinolytic parameters.
Fibrinogen significantly decreased with the combination
treatment (2.48 ± 0.65 to 1.99 ± 0.62 g/L, p = 0.008), but not
with simvastatin (2.71 ± 0.72 to 2.68 ± 0.75 g/L, p = 0.846)
(Figure 1). There was no change in d-dimer after both
treatments (0.30 ±  0.12 to 0.35 ±  0.19 μg/mL, p = 0.055 in
combination group; 0.33 ± 0.17 to 0.29 ± 0.14 μg/mL, p =
0.155 in simvastatin group) (Figure 2).
Table 2. Lipid profile before and after treatment*
Baseline 12th week p
LDL-C
Niacin ER plus lovastatin 161.4 ± 21.6 110.8 ± 25.2 < 0.001
Simvastatin 159.9 ± 25.6 102.1 ± 26.0 < 0.001
TC
Niacin ER plus lovastatin 241.8 ± 26.2 191.0 ± 32.1 < 0.001
Simvastatin 238.8 ± 28.3 172.7 ± 28.7 < 0.001
HDL-C
Niacin ER plus lovastatin 45.2 ± 11.7 49.2 ± 12.5 0.003
Simvastatin 42.7 ± 8.6 43.7 ± 10.7 0.371
TG
Niacin ER plus lovastatin 129.9 ± 68.8 118.4 ± 47.2 0.672
Simvastatin 155.7 ± 83.2 115.2 ± 52.3 0.017
*Values are shown as mean ± standard deviation. LDL-C = low-density lipoprotein cholesterol; ER = extended-release; TC = total cholesterol;
HDL-C = high-density lipoprotein cholesterol; TG = triglyceride.
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DISCUSSION
This study had three findings. First, both niacin extended-
release plus lovastatin and simvastatin were shown to be
comparatively effective in decreasing LDL-C and TC.
Second, both treatments were well tolerated in our study
subjects. Third, treatment with niacin extended-release plus
lovastatin may provide additional benefits in fibrinolysis.
Research into experimental animals, laboratory
investigations, epidemiology, and genetic forms of
hypercholesterolemia indicate that elevated LDL-C is a
major cause of CHD [1]. In addition, recent clinical trials
robustly show that LDL-lowering therapy reduces the risk
for CHD [2,3] and, hence, the NCEP-ATP III continues to
identify elevated LDL-C as the primary target of cholesterol-
lowering therapy. As a result, the primary goals of therapy
and the cut-off points for initiating treatment are stated in
terms of LDL [9]. Lessons from recent endpoint trials of
lipid-lowering drugs indicated that patients at very high
Table 3. Adverse events
p
Niacin extended-release plus lovastatin Simvastatin
Mild Moderate Severe Total Mild Moderate Severe Total
Cardiovascular system
Arrhythmia 0.75 3 (8.6%) 0 (0.0%) 0 (0.0%) 3 (8.6%) 1 (3.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%)
Arteriosclerosis 0.59 4 (11.4%) 0 (0.0%) 0 (0.0%) 4 (11.4%) 2 (6.1%) 0 (0.0%) 0 (0.0%) 2 (6.1%)
Cardiovascular disorder 0.13 8 (22.9%) 1 (2.9%) 0 (0.0%) 9 (25.7%) 11 (33.3%) 1 (3.0%) 0 (0.0%) 12 (36.4%)
Myocardial ischemia 0.65 3 (8.6%) 0 (0.0%) 0 (0.0%) 3 (8.6%) 2 (6.1%) 0 (0.0%) 0 (0.0%) 2 (6.1%)
Palpitation 0.49 6 (17.1%) 0 (0.0%) 0 (0.0%) 6 (17.1%) 2 (6.1%) 0 (0.0%) 0 (0.0%) 2 (6.1%)
Pericardial effusion 0.75 1 (2.9%) 0 (0.0%) 0 (0.0%) 1 (2.9%) 3 (9.1%) 0 (0.0%) 0 (0.0%) 3 (9.1%)
Vascular disorder 0.67 5 (14.3%) 0 (0.0%) 0 (0.0%) 5 (14.3%) 1 (3.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%)
Digestive system
Dyspepsia 0.54 2 (5.7%) 0 (0.0%) 0 (0.0%) 2 (5.7%) 5 (15.2%) 0 (0.0%) 0 (0.0%) 5 (15.2%)
Flatulence 0.65 2 (5.7%) 0 (0.0%) 0 (0.0%) 2 (5.7%) 3 (9.1%) 0 (0.0%) 0 (0.0%) 3 (9.1%)
Nausea 0.75 1 (2.9%) 0 (0.0%) 0 (0.0%) 1 (2.9%) 3 (9.1%) 0 (0.0%) 0 (0.0%) 3 (9.1%)
Musculoskeletal system
Edema/cramp/pain 0.71 7 (20.0%) 0 (0.0%) 1 (2.9%) 8 (22.9%) 2 (6.1%) 0 (0.0%) 0 (0.0%) 2 (6.1%)
Nervous system
Dizziness 0.07 8 (22.9%) 0 (0.0%) 0 (0.0%) 8 (22.9%) 7 (21.2%) 4 (12.1%) 0 (0.0%) 11 (33.3%)
Insomnia 0.59 4 (11.4%) 0 (0.0%) 0 (0.0%) 4 (11.4%) 2 (6.1%) 0 (0.0%) 0 (0.0%) 2 (6.1%)
Respiratory system
Cough and sputum 0.30 3 (8.6%) 0 (0.0%) 0 (0.0%) 3 (8.6%) 8 (24.2%) 0 (0.0%) 0 (0.0%) 8 (24.2%)
Pharyngitis 0.50 3 (8.6%) 0 (0.0%) 0 (0.0%) 3 (8.6%) 4 (12.1%) 0 (0.0%) 0 (0.0%) 4 (12.1%)
Skin and appendages
Pruritus or rash 0.59 2 (5.7%) 0 (0.0%) 0 (0.0%) 2 (5.7%) 4 (12.1%) 0 (0.0%) 0 (0.0%) 4 (12.1%)
risk for CHD benefit from treatment that decreases LDL-C
plasma levels to ) 70 mg/dL, that patients with * 2 risk
factors benefit from treatment that decrease plasma LDL-C
to < 100 mg/dL, and that a significant reduction in CHD
event rates is most often associated with a minimum plasma
LDL-C reduction of 30%. Recently, the NCEP-ATP III
recommendations were amended to incorporate these
lessons [10]. To reach these more aggressive goals and
plasma LDL-C reductions, more aggressive therapies and
even combination therapy will be required.
Both statin and niacin have demonstrated clinical trial
evidence of reducing coronary artery disease events and
overall mortality [2–5]. Because statins and niacin may have
potentially complementary actions, the combination of these
two lipid-lowering drugs with different mechanisms of
action has been studied, demonstrating greater reductions
in LDL-C than with each agent alone [11–14]. Nicotinic acid
is known as the most effective lipid drug for raising values
of plasma HDL-C [9]. In an informative angiographic clinical
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Figure 1. Fibrinogen change before and after treatment: (A) niacin extended-release plus lovastatin; (B) simvastatin.
Figure 2. d-Dimer change before and after treatment: (A) niacin extended-release plus lovastatin; (B) simvastatin.
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trial in men and women with low values of plasma HDL-C
cholesterol, combination treatment with nicotinic acid and
statin was more effective in significantly increasing HDL-C,
decreasing LDL-C and coronary angiographic progression
compared with placebo [15]. Previous study showed that a
once-daily niacin extended-release/lovastatin fixed-dose
combination was effective in reducing LDL-C and increasing
HDL-C in a Caucasian population [16]. In this study, the
same combination treatment was also effective in decreasing
LDL-C and increasing HDL-C in a Taiwanese population.
This combination therapy, however, may be associated
with serious side effects as concomitant use of niacin and
statin is associated with an increased risk of myopathy.
Additionally, niacin used either in monotherapy or
co-administration therapy is associated with vasodilatory
side effects that are intolerable to some patients [17]. This
face flush has been shown to lead to discontinuation of
therapy in patients taking niacin [16,18]. In our study
population, no subjects complained of significant face
flush. There have been several reports indicating a higher
incidence of liver toxicity with sustained release of nicotinic
acid [19]. Although the mechanism of hepatic injury remains
unknown, evidence implicates a dose-related toxicity and
not a hypersensitivity reaction [20]. The hepatotoxic effects
of niacin are usually transient with evidence of both
cholestasis and hepatocellular injury, and histopathologic
findings are consistent with centrilobular cholestasis and
parenchymal necrosis [21]. Although there were mild
elevations of liver enzymes, no subject in this study was
required to discontinue treatment at the investigator’s
discretion. Few reports have discussed the tolerability of
combination treatment with niacin and statin in Orientals.
Our study showed that combination therapy was well
tolerated, but with mild liver function impairment, in the
Taiwanese population.
There was some basic clinical evidence that reductions
in cardiovascular risk with statin are dependent on
mechanisms beyond cholesterol reduction alone, such as
modulation of procoagulant activity [22]. Recent evidence
suggests that most of these effects are mediated by the
inhibitory effect of statins on isoprenoid synthesis [23].
Limited studies have investigated the niacin effect on
fibrinolytic activity. Some results suggest that niacin may
potentiate fibrinolysis [24,25]. The mechanism of this
favorable effect in fibrinolysis after niacin treatment is still
unclear. In our study, those who received combination
treatment had significantly decreased fibrinogen after 16
weeks’ treatment, although niacin extended-release plus
lovastatin and simvastatin had the same degree of LDL-C
and TC lowering. However, the result is preliminary and
more work will be necessary to clarify the effects of niacin
and combination treatment on fibrinolytic function.
The major limitation of our investigation is the small
number of patients. Treatment with niacin extended-release
plus lovastatin may improve the fibrinolytic profile in
patients with dyslipidemia, but this requires confirmation
from more extensive clinical data.
CONCLUSION
Once-daily administration of niacin extended-release plus
lovastatin is effective and is a well-tolerated lipid-lowering
agent in Taiwanese patients with dyslipidemia. Sixteen-
week treatment with niacin extended-release plus lovastatin
also significantly reduced fibrinogen. This effect may
provide additional cardiovascular benefit.
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